301 related articles for article (PubMed ID: 31335338)
21. Effect of edaravone therapy in Korean amyotrophic lateral sclerosis (ALS) patients.
Park JM; Kim SY; Park D; Park JS
Neurol Sci; 2020 Jan; 41(1):119-123. PubMed ID: 31471712
[TBL] [Abstract][Full Text] [Related]
22. Edaravone in the treatment of amyotrophic lateral sclerosis: efficacy and access to therapy - a roundtable discussion.
Brooks BR; Jorgenson JA; Newhouse BJ; Shefner JM; Agnese W
Am J Manag Care; 2018 Apr; 24(9 Suppl):S175-S186. PubMed ID: 29693363
[TBL] [Abstract][Full Text] [Related]
23. [Drugs for Amyotrophic Lateral Sclerosis].
Ogino M
Brain Nerve; 2023 May; 75(5):503-506. PubMed ID: 37194520
[TBL] [Abstract][Full Text] [Related]
24. New Adamantane-Containing Edaravone Conjugates as Potential Neuroprotective Agents for ALS Treatments.
Lapshina MA; Shevtsova EF; Grigoriev VV; Aksinenko AY; Ustyugov AA; Steinberg DA; Maleev GV; Dubrovskaya ES; Goreva TV; Epishina TA; Zamoyski VL; Makhaeva GF; Fisenko VP; Veselov IM; Vinogradova DV; Bachurin SO
Molecules; 2023 Nov; 28(22):. PubMed ID: 38005288
[TBL] [Abstract][Full Text] [Related]
25. Edaravone Oral Suspension: A Neuroprotective Agent to Treat Amyotrophic Lateral Sclerosis.
Singh P; Belliveau P; Towle J; Neculau AE; Dima L
Am J Ther; 2024 May-Jun 01; 31(3):e258-e267. PubMed ID: 38691665
[TBL] [Abstract][Full Text] [Related]
26. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
Miller RG; Mitchell JD; Lyon M; Moore DH
Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
[TBL] [Abstract][Full Text] [Related]
27. Edaravone for amyotrophic lateral sclerosis: barriers to access and lifeboat ethics.
Breiner A; Zinman L; Bourque PR
CMAJ; 2020 Mar; 192(12):E319-E320. PubMed ID: 32392516
[No Abstract] [Full Text] [Related]
28. ALS drug development: reflections from the past and a way forward.
Aggarwal S; Cudkowicz M
Neurotherapeutics; 2008 Oct; 5(4):516-27. PubMed ID: 19019302
[TBL] [Abstract][Full Text] [Related]
29. Toward more efficient clinical trials for amyotrophic lateral sclerosis.
Cudkowicz ME; Katz J; Moore DH; O'Neill G; Glass JD; Mitsumoto H; Appel S; Ravina B; Kieburtz K; Shoulson I; Kaufmann P; Khan J; Simpson E; Shefner J; Levin B; Cwik V; Schoenfeld D; Aggarwal S; McDermott MP; Miller RG
Amyotroph Lateral Scler; 2010 May; 11(3):259-65. PubMed ID: 19961263
[TBL] [Abstract][Full Text] [Related]
30. Clinical staging in amyotrophic lateral sclerosis: analysis of Edaravone Study 19.
Al-Chalabi A; Chiò A; Merrill C; Oster G; Bornheimer R; Agnese W; Apple S
J Neurol Neurosurg Psychiatry; 2021 Feb; 92(2):165-171. PubMed ID: 33109706
[TBL] [Abstract][Full Text] [Related]
31. Drug therapy for amyotrophic lateral sclerosis: Where are we now?
Carter GT; Krivickas LS; Weydt P; Weiss MD; Miller RG
IDrugs; 2003 Feb; 6(2):147-53. PubMed ID: 12789618
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of clinical outcome and safety profile of edaravone in treatment of amyotrophic lateral sclerosis: a 72-week single-center experience.
Ismail II; Massoud F; Kamel WA; Al-Hashel JY
Acta Neurol Belg; 2021 Dec; 121(6):1591-1597. PubMed ID: 32651875
[TBL] [Abstract][Full Text] [Related]
33. Edaravone and its clinical development for amyotrophic lateral sclerosis.
Takei K; Watanabe K; Yuki S; Akimoto M; Sakata T; Palumbo J
Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):5-10. PubMed ID: 28872907
[TBL] [Abstract][Full Text] [Related]
34. Current trends in the clinical trial landscape for amyotrophic lateral sclerosis.
van Eijk RPA; Kliest T; van den Berg LH
Curr Opin Neurol; 2020 Oct; 33(5):655-661. PubMed ID: 32796282
[TBL] [Abstract][Full Text] [Related]
35. Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: Grade 3, requiring assistance for eating, excretion or ambulation).
WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 18 STUDY GROUP
Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):40-48. PubMed ID: 28872915
[TBL] [Abstract][Full Text] [Related]
36. A perspective on therapies for amyotrophic lateral sclerosis: can disease progression be curbed?
Xu X; Shen D; Gao Y; Zhou Q; Ni Y; Meng H; Shi H; Le W; Chen S; Chen S
Transl Neurodegener; 2021 Aug; 10(1):29. PubMed ID: 34372914
[TBL] [Abstract][Full Text] [Related]
37. Gold Coast criteria expand clinical trial eligibility in amyotrophic lateral sclerosis.
Jewett G; Khayambashi S; Frost GS; Beland B; Lee A; Hodgkinson V; Korngut L; Chhibber S
Muscle Nerve; 2022 Oct; 66(4):397-403. PubMed ID: 35673968
[TBL] [Abstract][Full Text] [Related]
38. Designing clinical trials in amyotrophic lateral sclerosis.
Shefner JM
Phys Med Rehabil Clin N Am; 2008 Aug; 19(3):495-508, ix. PubMed ID: 18625412
[TBL] [Abstract][Full Text] [Related]
39. Clinical studies in amyotrophic lateral sclerosis.
Dorst J; Genge A
Curr Opin Neurol; 2022 Oct; 35(5):686-692. PubMed ID: 35942672
[TBL] [Abstract][Full Text] [Related]
40. A post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis.
EDARAVONE (MCI-186) ALS 16 STUDY GROUP
Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):11-19. PubMed ID: 28872917
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
